bisphosphonate


Also found in: Medical, Wikipedia.

bis·phos·pho·nate

 (bĭs′fŏs′fə-nāt′)
n.
Any of a class of drugs that decrease bone resorption by inhibiting osteoclasts, used in the treatment of osteoporosis, Paget's disease, bone metastases, and other conditions. Also called diphosphonate.

[bis- + phosphon(ic acid), phosphorous acid (from phosphonium) + -ate.]

bisphosphonate

(ˌbɪsˈfɒsfəneɪt)
n
(Pharmacology) any drug of a class that inhibits the resorption of bone; used in treating certain bone disorders, esp osteoporosis
Translations

bisphosphonate

n bisfosfonato
References in periodicals archive ?
Bisphosphonate drugs are a common treatment used in individuals with osteoporosis.
AMSTERDAM--Older women on bisphosphonate treatment for at least 3 years who then stopped taking the drug showed a 40% increased risk for hip fracture after they were off the bisphosphonate for more than 2 years, compared with women who never stopped using the drug, according to an analysis of more than 150,000 women in a Medicare database.
Pamidronate-a bisphosphonate, was given I/V on monthly basis along with oral calcium.
Bisphosphonate drugs, such as alendronate (Fosamax), ibandronate (Boniva) and zoledronic acid (Reclast), are proven to combat bone loss and fractures in people with the bone-thinning disease osteoporosis.
Just under one-quarter of the women were on bisphosphonate therapy.
Several large, population-based, case-control studies have found a temporal relationship between bisphosphonate therapy and a statistically significant increased risk of subtrochanteric fractures.
Long-term bisphosphonate use has been suggested to result in suppressed bone remodelling and an increased risk of atypical fractures [1].
Bisphosphonates are specific inhibitors of osteoclastic activity and they reduce pathological fractures, skeletal related events and pain, and improve the quality of life in patients with metastatic cancers and multiple myeloma.1,2 Although usage of bisphosphonates is thought to be safe, in 2003, Marx and Stern reported the Bisphosphonate related osteonecrosis of the jaws (BRONJ).3 Nomenclature of this phenomenon changed as medication related osteonecrosis of the jaws (MRONJ ) in 2014.
The vast majority of atypical femur fractures are seen after long-term bisphosphonate use, and many doctors now recommend a five-year limit for taking them, with a periodic assessment of whether the drug is still necessary.
All randomized or prospective matched controlled trials that assessed the efficacy of bisphosphonate for elderly patients with hip fracture were included.
UCB today announced detailed Phase 3 results showing the investigational agent romosozumab demonstrated a statistically significant increase in hip bone mineral density (BMD) and strength compared with teriparatide in postmenopausal women with osteoporosis transitioning from bisphosphonate treatment.